Avantor (NYSE:AVTR) Sets New 52-Week High – Here’s What Happened

Shares of Avantor, Inc. (NYSE:AVTR) reached a new 52-week high during mid-day trading on Tuesday. The stock traded as high as $16.38 and last traded at $15.8730, with a volume of 355253 shares trading hands. The stock had previously closed at $15.81.

Analyst Ratings Changes

Several research firms recently issued reports on AVTR. Morgan Stanley increased their target price on Avantor from $10.00 to $14.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 30th. UBS Group began coverage on Avantor in a research report on Wednesday, September 9th. They issued a “neutral” rating and a $16.00 target price for the company. Wells Fargo & Company boosted their price target on shares of Avantor from $14.00 to $16.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. Citigroup increased their price target on shares of Avantor from $9.00 to $11.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Finally, Wolfe Research raised shares of Avantor from a “strong sell” rating to a “hold” rating in a research note on Thursday, July 30th. Two equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Avantor has an average rating of “Hold” and an average price target of $12.88.

Avantor Stock Performance

The stock has a market capitalization of $10.38 billion, a PE ratio of -18.28, a price-to-earnings-growth ratio of 11.65 and a beta of 0.94. The company has a quick ratio of 1.18, a current ratio of 1.78 and a debt-to-equity ratio of 0.65. The stock has a fifty day moving average of $14.60 and a 200-day moving average of $11.03.

Avantor (NYSE:AVTR) last issued its quarterly earnings results on Wednesday, July 29th. The company reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.02. The company had revenue of $1.69 billion for the quarter, compared to the consensus estimate of $1.61 billion. Avantor had a positive return on equity of 9.92% and a negative net margin of 8.81%.Avantor’s revenue was up .5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.24 EPS. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. Equities analysts anticipate that Avantor, Inc. will post 0.81 earnings per share for the current fiscal year.

Institutional Trading of Avantor

Large investors have recently made changes to their positions in the company. Elevation Wealth Partners LLC lifted its stake in Avantor by 72.3% in the third quarter. Elevation Wealth Partners LLC now owns 2,803 shares of the company’s stock worth $42,000 after acquiring an additional 1,176 shares during the last quarter. SJS Investment Consulting Inc. increased its position in shares of Avantor by 1,599.7% in the 1st quarter. SJS Investment Consulting Inc. now owns 5,235 shares of the company’s stock valued at $41,000 after purchasing an additional 4,927 shares during the last quarter. IFP Advisors Inc increased its position in shares of Avantor by 901.4% in the 2nd quarter. IFP Advisors Inc now owns 5,858 shares of the company’s stock valued at $58,000 after purchasing an additional 5,273 shares during the last quarter. State of Wyoming acquired a new stake in shares of Avantor in the 2nd quarter valued at $74,000. Finally, Parallel Advisors LLC raised its holdings in shares of Avantor by 21.4% in the 1st quarter. Parallel Advisors LLC now owns 8,452 shares of the company’s stock valued at $66,000 after purchasing an additional 1,491 shares in the last quarter. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Avantor Company Profile

Avantor, Inc is a global provider of products, services and solutions used in the life sciences and advanced technology industries. The company supplies materials and equipment that support research, drug discovery and development, biopharmaceutical manufacturing, clinical and diagnostic activities, and other laboratory applications.

Its offerings include laboratory chemicals and reagents, consumables, single-use manufacturing technologies, bioprocessing products, equipment, and related services.